Bitran J D, Vokes E E
Section of Hematology/Oncology, Pritzker School of Medicine, University of Chicago, Illinois.
Hematol Oncol Clin North Am. 1990 Dec;4(6):1159-68.
Chemotherapy regimens with consistent activities in NSCLC have been identified. A modest but statistically significant increase in survival has been shown in a single large randomized trial, with three smaller trials showing either similar results or a trend toward an improved survival. However, chemotherapy-related toxicity remains significant and seems exacerbated in patients with a poor performance status at the time of diagnosis. Identification of chemotherapy regimens with higher activity in NSCLC remains a necessity, and the treatment of stage IV patients on clinical trials should be encouraged. Outside the context of a clinical trial, chemotherapy is indicated in selected stage IV patients with good performance status in an attempt to palliate their symptoms and increase their survival.
已确定在非小细胞肺癌（NSCLC）中具有一致活性的化疗方案。在一项大型随机试验中显示生存期有适度但具有统计学意义的增加，三项较小的试验显示出类似结果或生存期改善趋势。然而，化疗相关毒性仍然很大，并且在诊断时体能状态较差的患者中似乎更为严重。确定在NSCLC中具有更高活性的化疗方案仍然很有必要，并且应鼓励对IV期患者进行临床试验治疗。在临床试验背景之外，对于体能状态良好的部分IV期患者，可使用化疗以缓解其症状并延长生存期。
